This article is more than 5 years old. Information may no longer be current.

Carl Zeiss Meditec posts 7.2% rise in consolidated revenue for first 9 months of fiscal year

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

JENA, Germany — Carl Zeiss Meditec generated €478.5 million in consolidated revenue for the first 9 months of its fiscal year, representing a 7.2% increase compared with €446.6 million reported during the same period a year ago, the company announced in a press release.

The company's earnings before interest and taxes totaled €53.6 million for the first 9 months of the fiscal period, representing an 11% gain compared with €48.3 million during the comparable period last year.

Due to declining interest rates on capital investments, 9-month consolidated net income after minority interests totaled €32.5 million, or €0.40 per share, down from €36.4 million, or €0.45 per share, reported during the same 9-month period last year.

Bolstered by currency development of the dollar and the yen against the Euro, Carl Zeiss Meditec's ophthalmic systems strategic business unit, which contributed 48.5% of the company's revenue during the first 9 months of the fiscal year, posted €232.2 in revenue, up 13.2% from €205.1 million during the comparable period last year.

Based on IOL sales growth, revenues for the company's surgical ophthalmology strategic business unit grew by 5.3% to €61.6 million during the 9-month period. However, due to a decline in hospital sector investments, revenues for the company's microsurgery strategic unit showed little growth, stabilizing at €184.7 million.

Because of strong diagnostic and surgical revenues, the Americas region generated the company's highest sales during the first 9 months of the fiscal year, posting €165.7 million in revenue, up 9.6% from €151.2 million during the same period last year, according to the release.

Based on strong sales in Japan and India, the company's Asia-Pacific region generated €128.2 in revenue for the 9-month period, up 20.2% from €106.7 million during the same period last year.

Sales for the company's Europe, Middle East and Africa region totaled €144.8 million during the 9-month period, down slightly from €149 million during the same period last year.

Carl Zeiss Meditec expects revenue to grow by at least 5% with stabilized profitability for the full financial year.